MeSH term
Frequency | Condition_Probility | Female | 138 | 0.0 |
Humans | 281 | 0.0 |
Pregnancy | 9 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Sensitivity and Specificity | 7 | 0.0 |
Animals | 83 | 0.0 |
Fragile X Syndrome/*diagnosis/genetics | 3 | 42.0 |
Immunohistochemistry | 6 | 0.0 |
Infant, Newborn | 5 | 0.0 |
Male | 191 | 0.0 |
Polymerase Chain Reaction | 35 | 0.0 |
*RNA-Binding Proteins | 160 | 52.0 |
Repetitive Sequences, Nucleic Acid | 12 | 1.0 |
Research Support, Non-U.S. Gov't | 192 | 0.0 |
Adolescent | 39 | 0.0 |
Adult | 45 | 0.0 |
Child | 48 | 0.0 |
Cognition/*physiology | 2 | 2.0 |
Fragile X Syndrome/genetics/*physiopathology | 2 | 100.0 |
Gene Expression/physiology | 2 | 0.0 |
Nerve Tissue Proteins/*genetics | 106 | 17.0 |
Research Support, U.S. Gov't, P.H.S. | 104 | 0.0 |
Wechsler Scales | 4 | 25.0 |
Amino Acid Sequence | 29 | 0.0 |
Disease Models, Animal | 13 | 0.0 |
Fragile X Syndrome/*genetics | 100 | 64.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Mice | 49 | 0.0 |
Mice, Knockout | 24 | 0.0 |
Molecular Sequence Data | 81 | 0.0 |
Nerve Tissue Proteins/genetics | 25 | 9.0 |
RNA-Binding Proteins/genetics | 11 | 19.0 |
Sequence Alignment | 8 | 0.0 |
Sequence Homology, Amino Acid | 13 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Base Sequence | 73 | 0.0 |
*Chromosomal Proteins, Non-Histone | 3 | 1.0 |
Chromosome Mapping | 23 | 0.0 |
Comparative Study | 41 | 0.0 |
CpG Islands/genetics | 4 | 2.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
*Gene Frequency | 2 | 0.0 |
Mental Retardation/*genetics | 26 | 12.0 |
Reference Values | 9 | 0.0 |
Sex Characteristics | 5 | 0.0 |
X Chromosome | 11 | 2.0 |
Alleles | 29 | 0.0 |
Dosage Compensation (Genetics) | 6 | 4.0 |
Gene Expression | 13 | 0.0 |
Gestational Age | 2 | 0.0 |
*Mutation | 13 | 0.0 |
X Chromosome/genetics | 5 | 2.0 |
CpG Islands | 6 | 2.0 |
DNA Methylation | 20 | 2.0 |
*Gene Expression Regulation | 8 | 0.0 |
*Gene Silencing | 4 | 2.0 |
Models, Biological | 4 | 0.0 |
Promoter Regions (Genetics) | 10 | 0.0 |
*Transcription, Genetic | 6 | 0.0 |
Fragile X Syndrome/epidemiology/*genetics | 4 | 100.0 |
Prevalence | 5 | 0.0 |
Nerve Tissue Proteins/*deficiency/genetics | 2 | 25.0 |
Models, Animal | 2 | 0.0 |
*Cognition | 2 | 4.0 |
Neuropsychological Tests | 3 | 1.0 |
*Trinucleotide Repeats | 28 | 24.0 |
*Alleles | 10 | 0.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Risk Factors | 6 | 0.0 |
Trinucleotide Repeat Expansion/*genetics | 8 | 13.0 |
Aged | 20 | 0.0 |
Case-Control Studies | 6 | 0.0 |
*Chromosomes, Human, X | 4 | 13.0 |
*Heterozygote | 10 | 3.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Intelligence/genetics | 3 | 37.0 |
Intelligence Tests | 10 | 19.0 |
Middle Aged | 23 | 0.0 |
Nerve Tissue Proteins/genetics/metabolism | 3 | 4.0 |
RNA, Messenger/biosynthesis | 6 | 0.0 |
RNA-Binding Proteins/genetics/metabolism | 2 | 7.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 4 | 1.0 |
Trinucleotide Repeat Expansion/genetics | 5 | 12.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Mutation/*genetics | 11 | 0.0 |
Nerve Tissue Proteins/genetics/*metabolism | 6 | 4.0 |
RNA-Binding Proteins/genetics/*metabolism | 4 | 6.0 |
Rats | 4 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Fragile X Syndrome/*genetics/*pathology | 2 | 66.0 |
Nerve Tissue Proteins/*deficiency/*genetics/physiology | 2 | 66.0 |
Fragile X Syndrome/*genetics/pathology/*psychology | 2 | 100.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Behavior, Animal | 4 | 5.0 |
Chromosomes, Artificial, Yeast | 3 | 0.0 |
Cognition | 4 | 7.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Gene Therapy | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Mice, Transgenic | 6 | 0.0 |
Phenotype | 30 | 0.0 |
Testis/pathology | 5 | 10.0 |
English Abstract | 10 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Genetics, Population | 3 | 0.0 |
Heterozygote | 9 | 0.0 |
Polymorphism, Genetic | 8 | 0.0 |
Trinucleotide Repeats | 19 | 16.0 |
Cell Line | 17 | 0.0 |
Child, Preschool | 27 | 0.0 |
Fragile X Syndrome/*genetics/physiopathology | 3 | 100.0 |
Karyotyping | 4 | 0.0 |
Mosaicism/*genetics | 2 | 5.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Sequence Deletion/*genetics | 2 | 1.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Blotting, Southern | 19 | 0.0 |
Point Mutation/*genetics | 4 | 1.0 |
Trinucleotide Repeats/*genetics | 16 | 20.0 |
RNA-Binding Proteins/*genetics | 18 | 14.0 |
Tissue Distribution | 5 | 0.0 |
DNA | 3 | 0.0 |
Exons | 13 | 0.0 |
Introns | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
*X Chromosome | 23 | 2.0 |
Gene Expression Regulation | 4 | 0.0 |
Genes, Insect | 2 | 3.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Intelligence | 3 | 9.0 |
Nerve Tissue Proteins/analysis | 3 | 4.0 |
Regression Analysis | 3 | 0.0 |
Sex Factors | 8 | 0.0 |
Social Environment | 2 | 11.0 |
Asia | 3 | 4.0 |
DNA/genetics | 6 | 0.0 |
Fragile X Syndrome/genetics | 15 | 45.0 |
Gene Frequency | 10 | 0.0 |
Microsatellite Repeats | 7 | 0.0 |
Fragile X Syndrome/genetics/*metabolism/pathology | 2 | 100.0 |
Immunoblotting | 2 | 0.0 |
Lymphocytes/metabolism | 4 | 1.0 |
Mutation | 34 | 0.0 |
Mental Retardation, X-Linked/*genetics | 3 | 15.0 |
Family Health | 2 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Fragile X Syndrome/*epidemiology/*genetics | 3 | 100.0 |
Gene Frequency/genetics | 2 | 0.0 |
Genetic Screening | 9 | 1.0 |
Trinucleotide Repeats/genetics | 5 | 8.0 |
DNA/chemistry/genetics | 6 | 0.0 |
*DNA Methylation | 7 | 1.0 |
DNA Mutational Analysis | 8 | 0.0 |
Fragile X Syndrome/diagnosis/*genetics | 6 | 46.0 |
Polymerase Chain Reaction/methods | 7 | 0.0 |
Pan troglodytes | 2 | 1.0 |
Phylogeny | 2 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
X Chromosome/*genetics | 13 | 3.0 |
Genetic Screening/*methods | 3 | 2.0 |
Mosaicism/genetics | 3 | 14.0 |
Leukocytes/metabolism | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
5' Untranslated Regions/genetics | 2 | 1.0 |
Linkage (Genetics) | 7 | 0.0 |
Mental Retardation/genetics | 9 | 7.0 |
Nerve Tissue Proteins/*chemistry/*genetics | 2 | 40.0 |
Brain/pathology | 5 | 1.0 |
Magnetic Resonance Imaging | 5 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Fragile X Syndrome/epidemiology/genetics | 3 | 100.0 |
Haplotypes | 15 | 0.0 |
*Nuclear Proteins | 8 | 0.0 |
Proteins/*genetics | 7 | 0.0 |
Sequence Analysis, DNA | 13 | 0.0 |
*Trans-Activators | 8 | 1.0 |
*Chromosome Mapping | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Cloning, Molecular | 10 | 0.0 |
Gene Library | 2 | 0.0 |
Nucleic Acid Conformation | 6 | 1.0 |
Trinucleotide Repeat Expansion | 6 | 16.0 |
CpG Islands/*genetics | 2 | 2.0 |
*Linkage (Genetics) | 4 | 0.0 |
Pedigree | 36 | 0.0 |
Ovarian Failure, Premature/*genetics | 3 | 20.0 |
Diagnosis, Differential | 2 | 0.0 |
Incidence | 2 | 0.0 |
Mental Retardation/epidemiology/*genetics | 2 | 50.0 |
Netherlands/epidemiology | 3 | 2.0 |
Aged, 80 and over | 6 | 0.0 |
Blotting, Southern/methods | 3 | 11.0 |
Genotype | 8 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
DNA Footprinting | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Molecular Conformation | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Fragile X Syndrome/*diagnosis/*genetics | 5 | 83.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Asparagine/genetics | 2 | 5.0 |
Isoleucine/genetics | 2 | 7.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Oocytes/metabolism | 2 | 1.0 |
*Protein Biosynthesis | 4 | 0.0 |
Rabbits | 2 | 0.0 |
Xenopus laevis | 2 | 0.0 |
Acoustic Stimulation | 2 | 2.0 |
*Maze Learning | 2 | 100.0 |
Asian Continental Ancestry Group/genetics | 3 | 0.0 |
China/ethnology | 2 | 1.0 |
5' Untranslated Regions | 2 | 1.0 |
Methylation | 13 | 2.0 |
Psychometrics | 2 | 3.0 |
Transcription, Genetic | 10 | 0.0 |
Blotting, Western | 5 | 0.0 |
Cell Division | 2 | 0.0 |
Cells, Cultured | 13 | 0.0 |
Clone Cells | 2 | 0.0 |
Nerve Tissue Proteins/*genetics/metabolism | 5 | 6.0 |
*Trinucleotide Repeat Expansion | 6 | 13.0 |
Fragile X Syndrome/*metabolism | 5 | 100.0 |
Binding Sites | 4 | 0.0 |
DNA/*chemistry/*genetics | 2 | 15.0 |
*Nucleic Acid Conformation | 2 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
*5' Untranslated Regions | 3 | 11.0 |
Genetic Markers | 11 | 0.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Schools | 3 | 37.0 |
Fragile X Syndrome/*diagnosis/*epidemiology/genetics | 2 | 100.0 |
Chromosome Disorders | 2 | 0.0 |
DNA/analysis | 5 | 0.0 |
Nerve Tissue Proteins/blood/*genetics | 2 | 66.0 |
Point Mutation | 3 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
DNA/blood | 2 | 1.0 |
*Mosaicism | 4 | 7.0 |
Nerve Tissue Proteins/deficiency/*genetics | 4 | 44.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Restriction Mapping | 8 | 0.0 |
Brain/metabolism | 4 | 0.0 |
Mental Disorders/genetics | 3 | 21.0 |
Magnetic Resonance Imaging/methods | 2 | 2.0 |
Minisatellite Repeats | 5 | 3.0 |
Hela Cells | 5 | 0.0 |
Sequence Deletion | 7 | 0.0 |
Transfection | 3 | 0.0 |
Fragile X Syndrome/genetics/*metabolism | 5 | 83.0 |
Gene Deletion | 4 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
DNA Modification Methylases/metabolism | 2 | 25.0 |
DNA Primers | 15 | 0.0 |
Dinucleoside Phosphates | 2 | 11.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Family | 3 | 0.0 |
Fragile X Syndrome/ethnology/*genetics | 2 | 100.0 |
*Genetics, Population | 5 | 1.0 |
Greenland | 2 | 22.0 |
Inuits/*genetics | 2 | 15.0 |
Precipitin Tests | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Acetylation | 3 | 0.0 |
Azacitidine/analogs & derivatives/pharmacology | 2 | 8.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Histones/*metabolism | 3 | 2.0 |
Circular Dichroism | 3 | 0.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
Models, Genetic | 6 | 0.0 |
Protein Binding | 3 | 0.0 |
RNA/*metabolism | 2 | 3.0 |
Structure-Activity Relationship | 2 | 0.0 |
*DNA Replication | 4 | 1.0 |
*Dosage Compensation (Genetics) | 7 | 4.0 |
*In Situ Hybridization, Fluorescence | 2 | 1.0 |
Lymphocytes/cytology | 2 | 2.0 |
Blotting, Northern | 3 | 0.0 |
Nerve Tissue Proteins/*biosynthesis/genetics | 3 | 7.0 |
RNA-Binding Proteins/*biosynthesis/genetics | 2 | 40.0 |
Alternative Splicing | 3 | 0.0 |
Fetus | 2 | 0.0 |
Tandem Repeat Sequences | 2 | 1.0 |
Age Factors | 3 | 0.0 |
Fragile X Syndrome/blood/*genetics | 2 | 100.0 |
Molecular Weight | 2 | 0.0 |
Nuclear Family | 2 | 0.0 |
Crosses, Genetic | 3 | 0.0 |
Drosophila | 2 | 0.0 |
Drosophila Proteins/metabolism | 2 | 14.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
RNA, Messenger/*metabolism | 6 | 0.0 |
Ribonucleoproteins/*metabolism | 2 | 4.0 |
Chromosome Banding | 4 | 0.0 |
Fragile X Syndrome/complications/*genetics | 2 | 66.0 |
Genes, Structural/genetics | 2 | 0.0 |
Mice, Inbred Strains | 4 | 0.0 |
*Carrier Proteins | 4 | 0.0 |
Models, Molecular | 3 | 0.0 |
Nerve Tissue Proteins/chemistry | 2 | 10.0 |
Protein Structure, Secondary | 4 | 0.0 |
RNA-Binding Proteins/*chemistry | 4 | 30.0 |
Syndrome | 3 | 0.0 |
Mosaicism | 5 | 7.0 |
Brain/*pathology | 3 | 1.0 |
*Gene Deletion | 3 | 0.0 |
Cyprus/epidemiology | 2 | 20.0 |
Greece/epidemiology | 2 | 5.0 |
Hydroxamic Acids/pharmacology | 2 | 1.0 |
*Chromosome Deletion | 3 | 0.0 |
Fragile X Syndrome/*physiopathology | 2 | 100.0 |
Haplorhini | 3 | 1.0 |
Infant | 6 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Drosophila/genetics/metabolism | 2 | 20.0 |
Chromosome Fragile Sites | 5 | 3.0 |
Chromosome Fragility | 6 | 10.0 |
Spain | 2 | 0.0 |
Fragile X Syndrome/*genetics/metabolism | 2 | 50.0 |
*Gene Expression | 3 | 0.0 |
Neurons/*metabolism | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
*Haplotypes | 2 | 0.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
Nerve Tissue Proteins/*deficiency/*genetics | 2 | 100.0 |
Fragile X Syndrome/*genetics/pathology | 6 | 85.0 |
Heterozygote Detection | 7 | 1.0 |
Chromosome Aberrations | 2 | 0.0 |
Nerve Tissue Proteins/chemistry/genetics/*metabolism | 2 | 5.0 |
Protein Structure, Tertiary | 2 | 0.0 |
*Chromosome Fragility | 3 | 2.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
*Sequence Deletion | 7 | 1.0 |
Nerve Tissue Proteins/*biosynthesis/*genetics | 3 | 33.0 |
Time Factors | 7 | 0.0 |
Protein Biosynthesis | 4 | 0.0 |
RNA-Binding Proteins/*genetics/metabolism | 2 | 6.0 |
Antibodies, Monoclonal | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 10 | 0.0 |
Cell Cycle | 2 | 0.0 |
Fragile X Syndrome/diagnosis/*genetics/psychology | 2 | 100.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Conserved Sequence | 5 | 0.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
DNA/metabolism | 2 | 0.0 |
DNA Replication/*genetics | 2 | 3.0 |
*Point Mutation | 2 | 0.0 |
Child Development Disorders, Pervasive/*genetics | 2 | 66.0 |
Reproducibility of Results | 3 | 0.0 |
DNA Replication | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
Nerve Tissue Proteins/*genetics/physiology | 6 | 20.0 |
Organ Size | 2 | 1.0 |
Genetic Counseling | 3 | 1.0 |
*Founder Effect | 2 | 1.0 |
Hybrid Cells | 5 | 0.0 |
Protein Conformation | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 11 | 2.0 |
Hamsters | 4 | 0.0 |
Brain/embryology/metabolism | 2 | 3.0 |
Species Specificity | 4 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 3 | 2.0 |
DNA Primers/genetics | 3 | 0.0 |
Fragile X Syndrome/genetics/metabolism | 2 | 66.0 |
*Drosophila Proteins | 4 | 0.0 |
Nerve Tissue Proteins/*metabolism | 3 | 1.0 |
RNA-Binding Proteins/*genetics/*metabolism | 3 | 16.0 |
Forecasting | 2 | 0.0 |
Cognition Disorders/diagnosis | 2 | 15.0 |
Aging | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
RNA-Binding Proteins/genetics/physiology | 2 | 40.0 |
Severity of Illness Index | 2 | 0.0 |
Oligodeoxyribonucleotides/genetics | 2 | 2.0 |
*Disease Models, Animal | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Nerve Tissue Proteins/biosynthesis/genetics | 4 | 13.0 |
Heterogeneous-Nuclear Ribonucleoproteins | 2 | 1.0 |
*X Chromosome/physiology | 2 | 100.0 |
RNA-Binding Proteins/biosynthesis/genetics | 2 | 50.0 |
Fragile X Syndrome/*genetics/psychology | 2 | 66.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Brazil | 2 | 0.0 |
Gene Silencing | 2 | 0.0 |
Nerve Tissue Proteins/*genetics/*metabolism | 2 | 9.0 |
